The substantial dilution from this offering is a near-term negative for existing shareholders. Monitor the stock for potential downward pressure as the new shares enter the market. The extended cash runway into H2 2028 reduces near-term financing risk, but the clinical-stage nature of the pipeline means significant future capital may still be needed. Watch for any exercise of the underwriters' greenshoe option and for the resumption of ATM sales after the 30-day lock-up period.
Price Chart
Executive Summary
Crescent Biopharma priced an underwritten public offering of 8,094,793 ordinary shares at $14.50 per share and 525,897 pre-funded warrants at $14.499 per warrant, with gross proceeds of approximately $125.0 million. Net proceeds are expected to be ~$115.9 million ($133.5 million if the underwriters' option to purchase an additional 1,293,103 shares is exercised in full). The company estimates the funds will extend its cash runway into the second half of 2028. The offering represents significant dilution for existing shareholders, with an immediate dilution of $6.10 per share for new investors.
Key Facts
- Offering of 8,094,793 ordinary shares at $14.50/share and 525,897 pre-funded warrants at $14.499/warrant.
- Gross proceeds of approximately $125.0 million; net proceeds of ~$115.9 million (~$133.5 million if underwriters' option is exercised in full).
- Underwriters have a 30-day option to purchase up to an additional 1,293,103 ordinary shares.
- Net tangible book value per share post-offering is $8.40, representing immediate dilution of $6.10 per share for new investors.
- Company estimates current cash plus offering proceeds will fund operations into the second half of 2028.
- Pre-funded warrants have an exercise price of $0.001, are immediately exercisable, and do not expire.
- Insiders and certain stockholders are subject to a 60-day lock-up period.
- The company has a $200 million at-the-market (ATM) facility with Jefferies, with sales restricted until 30 days post-offering or full exercise of the underwriters' option.
Financial Impact
Gross proceeds of ~$125.0 million; net proceeds of ~$115.9 million (or ~$133.5 million with full exercise of the greenshoe). Dilution of $6.10 per share for new investors.
Risk Factors
- Immediate and substantial dilution to existing shareholders.
- Clinical-stage biotech with no approved products; pipeline execution risk remains high.
- Potential for further dilution from the $200 million ATM facility once the lock-up expires.
- No established trading market for the pre-funded warrants, limiting liquidity for those holders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CBIO) — Batch item 1 | 0001628280-26-048347 |
| Exhibit: exhibit41formofpre-fundedw.htm | 0001628280-26-048344 |
| Exhibit: exhibit51walkersopiniondeal.htm | 0001628280-26-048347 |
| Exhibit: exhibit52lathamopiniondeal.htm | 0001628280-26-048347 |
| Exhibit: exhibit992pricingpressrele.htm | 0001628280-26-048347 |
| Exhibit: exhibit991launchpressrelea.htm | 0001628280-26-048347 |
| Document: cbio-20260714.htm | 0001628280-26-048347 |
| Document: 0001628280-26-048347-index-headers.html | 0001628280-26-048347 |
| Document: 0001628280-26-048347-index.html | 0001628280-26-048347 |
| Document: 0001628280-26-048347.txt | 0001628280-26-048347 |
| 424B5 Filing (CBIO) — Batch item 11 | 0001628280-26-048344 |
| 8-K Filing (CBIO) — Batch item 12 | 0001628280-26-048347 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $11.84 | awaiting T+60 | — | $12.96 (+9.46%) |
Oct 15, 2026 11d ago | Press Release | $11.84 | awaiting T+60 | — | $12.96 (+9.46%) |
Oct 5, 2026 22d ago | Press Release | $13.94 | awaiting T+60 | — | $12.96 (−7.03%) |
Sep 18, 2026 5w ago | Insider Cluster | $16.25 | awaiting T+60 | — | $12.96 (−20.25%) |
Jul 30, 2026 12w ago | 8-K | $15.02 $12.82 | ▼ −14.65% | ▼ −17.11% | $12.96 (−13.72%) |
Jul 20, 2026 14w ago | Insider Buy | $16.64 $12.91 | ▼ −22.42% | ▼ −26.39% | $12.96 (−22.12%) |
Jul 15, 2026 14w ago | 8-K / 424B5 | $15.11 $14.91 | ▲ +1.32% | ▲ +5.03% | $12.96 (+14.23%) |
Jul 14, 2026 14w ago | Press Release | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $12.96 (+17.29%) |
Jul 14, 2026 14w ago | 424B5 | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $12.96 (+17.29%) |
Jul 13, 2026 15w ago | EFFECT | $15.69 $13.57 | ▼ −13.51% | ▼ −17.51% | $12.96 (−17.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers